Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041323 | 0.80 | TSHR (0.50) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL3913251 | 0.79 | ALDH1A1 (0.52) | TSHRSMN1; SMN2L3MBTL1RAB9AHSP90AB1 | |
| SCHEMBL14276269 | 0.77 | TSHR (0.50) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL5413464 | 0.76 | ALDH1A1 (0.45) | TSHRNPC1HTTALDH1A1LMNA | |
| SCHEMBL31456568 | 0.76 | ALDH1A1 (0.45) | TSHRNPC1HTTALDH1A1LMNA | |
| SCHEMBL23860789 | 0.76 | TSHR (0.54) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL1998718 | 0.74 | HSP90AB1 (0.51) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL18004111 | 0.74 | TSHR (0.47) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL16398644 | 0.73 | L3MBTL1 (0.55) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL18399214 | 0.72 | TSHR (0.44) | TSHRSMN1; SMN2L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106146473-B | Anti-angiogenesis compound | 宁波市方昌医药有限公司 | 2020-04-14 | — | — | CN | disclosed |
| EP-2997022-B1 | PYRIMIDIN-4-YL-OXY-1H-INDOLE-1-CARBOXAMIDE DERIVATIVE AND ITS USE | NOVARTIS AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-9604969-B2 | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9604969-B2 | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9604969-B2 | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| CN-106188001-A | A kind of Anti-angiogenic compounds | 宁波市方昌医药有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-106146473-A | A kind of Anti-angiogenic compounds | 宁波市方昌医药有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-104072481-B | Anti-angiogenesis compound | 宁波市方昌医药有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160115156-A1 | PYRIMIDIN-4-YL)OXY)-1H-INDOLE-1-CARBOXAMIDE DERIVATIVES AND USE THEREOF | NOVARTIS AG (CH) | 2016-04-28 | — | — | US | disclosed |
| US-20110112121-A1 | Pharmaceutical Compositions and Solid Forms | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20110112121-A1 | Pharmaceutical Compositions and Solid Forms | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| WO-2011003858-A2 | PHARMACEUTICAL COMPOSITIONS AND SOLID FORMS | NOVARTIS AG (CH) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003858-A2 | PHARMACEUTICAL COMPOSITIONS AND SOLID FORMS | NOVARTIS AG (CH) | 2011-01-13 | — | — | WO | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| CN-101400673-A | Heterobicyclic carboxamides as kinase inhibitors | NOVARTIS AG (CH) | 2009-04-01 | — | — | CN | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | TSHR 3579/4885SMN1; SMN2 4023/4885L3MBTL1 3804/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | TSHR 3900/4885SMN1; SMN2 4751/4885L3MBTL1 4766/4885 |
| US-20160115156-A1 | PYRIMIDIN-4-YL)OXY)-1H-INDOLE-1-CARBOXAMIDE DERIVATIVES AND USE THEREOF | IDO1, IDO2, TPH1 | TSHR 2839/4885SMN1; SMN2 1811/4885L3MBTL1 4319/4885 |
| US-20110112121-A1 | Pharmaceutical Compositions and Solid Forms | VEGFA, FLT1, FLT4 | TSHR 4199/4885SMN1; SMN2 477/4885L3MBTL1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.